<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35508892</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes.</ArticleTitle><Pagination><StartPage>136</StartPage><EndPage>141</EndPage><MedlinePgn>136-141</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27569</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Trials incorporating placebo-to-active treatment crossover are encouraged in fatal conditions like amyotrophic lateral sclerosis (ALS) but may underestimate active treatment survival benefit. Here, we apply methods for modeling survival without crossover, including the rank-preserving structural failure time model (RPSFTM), to data from the CENTAUR trial of sodium phenylbutyrate and taurursodiol (PB and TURSO) in ALS incorporating both randomized placebo-controlled and open-label extension (OLE) phases.</AbstractText><AbstractText Label="METHODS">Intent-to-treat (ITT) and RPSFTM survival analyses were performed with final data at a July 2020 cutoff date. Analyses of subgroups based on randomized treatment and OLE phase participation were also performed.</AbstractText><AbstractText Label="RESULTS">Hazard ratios (95% confidence intervals) of death for PB and TURSO versus participants initially on placebo were 0.57 (0.35-0.92) on ITT analysis and 0.39 (0.17-0.88) in the primary on-treatment RPSFTM analysis (p&#xa0;=&#xa0;.023). Median ITT survival duration for PB and TURSO (25.8&#xa0;mo) was 6.9&#xa0;mo longer than placebo (18.9&#xa0;mo) on ITT analysis and 10.6&#xa0;mo longer than the median RPSFTM-adjusted survival duration for placebo (15.2&#xa0;mo). Median survival duration was 18.8&#xa0;mo longer in the PB and TURSO-randomized subgroup who continued into the OLE phase versus the placebo-randomized subgroup who did not continue into the OLE phase (p&#x2009;&lt;&#x2009;.0001), although OLE phase selection bias may have potentially confounded these results.</AbstractText><AbstractText Label="DISCUSSION">Similar to the prespecified ITT analysis, post hoc analyses adjusting for treatment crossover in CENTAUR showed a significant survival benefit for PB and TURSO. Such methods may provide clinical context for observed survival outcomes in future ALS crossover trials.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0505-1168</Identifier><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>Claire</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6475-2795</Identifier><AffiliationInfo><Affiliation>Maple Health Group, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clarostat Consulting Ltd, Bollington, Cheshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cawson</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Formerly with Maple Health Group, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendrix</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pentara Corporation, Millcreek, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Samuel P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Pentara Corporation, Millcreek, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knowlton</LastName><ForeName>Newman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Pentara Corporation, Millcreek, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timmons</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Amylyx Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manuel</LastName><ForeName>Machelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Amylyx Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">crossover trial design</Keyword><Keyword MajorTopicYN="N">sodium phenylbutyrate and taurursodiol</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList><CoiStatement>Sabrina Paganoni reports research grants from Amylyx Pharmaceuticals, Revalesio Corporation, Alector Therapeutics, UCB, Biohaven Pharmaceuticals, Clene Nanomedicine, Prilenia Therapeutics, Seelos Therapeutics, The ALS Association, the American Academy of Neurology, the Centers for Disease Control, ALS Finding a Cure&#xae;, the Salah Foundation, the Spastic Paraplegia Foundation, the Muscular Dystrophy Association, I AM ALS, Tambourine, Target ALS, Columbia University, and the Cullen Education and Research Fund, and is a site principle investigator for studies funded by Alector Therapeutics, Cytokinetics, and Novus (formerly Anelixis) Therapeutics. Dr Paganoni also reports institutional consulting agreements with Amylyx Pharmaceuticals, Frequency Therapeutics, and SOLA Biosciences; personal consulting agreements with Cytokinetics, Arrowhead Pharmaceuticals, and Orthogonal Neuroscience; and honoraria from Medscape. Claire Watkins and Matthew Cawson report fees via the Maple Health Group from Amylyx Pharmaceuticals for conducting some of the analyses described in the submitted work. Suzanne Hendrix, Samuel P. Dixon, and Newman Knowlton are employees of Pentara Corporation. Jamie Timmons and Machelle Manuel are full&#x2010;time employees of Amylyx Pharmaceuticals. Merit Cudkowicz reports consulting fees from Faze, Regeneron, AB Sciences, Avexis, MT Pharma, Revalasio, Cytokinetics, Disarm, ALS Pharma, Immunity Pharma, Wave, Sunovian, Transposon, Quralis, Helixsmith, Locust Walk, and RRD and is a board member for Praxis, all outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>23</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35508892</ArticleId><ArticleId IdType="pmc">PMC9540225</ArticleId><ArticleId IdType="doi">10.1002/mus.27569</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrews JA, Jackson CE, Heiman&#x2010;Patterson TD, Bettica P, Brooks BR, Pioro EP. Real&#x2010;world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7&#x2013;8):509&#x2010;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz J. Disease&#x2010;modifying treatment of amyotrophic lateral sclerosis. Am J Manag Care. 2018;24(15 Suppl):S327&#x2010;S335.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207671</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate&#x2013;taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919&#x2010;930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, et al. Long&#x2010;term survival of participants in the CENTAUR trial of sodium phenylbutyrate&#x2010;taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31&#x2010;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishak KJ, Proskorovsky I, Korytowsky B, Sandin R, Faivre S, Valle J. Methods for adjusting for bias due to crossover in oncology trials. Pharmacoeconomics. 2014;32(6):533&#x2010;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">24595585</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf6;nsson L, Sandin R, Ekman M, et al. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Value Health. 2014;17(6):707&#x2010;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">25236994</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu&#x2010;Seifert H, Andersen SW, Lipkovich I, Holdridge KC, Siemers E. A novel approach to delayed&#x2010;start analyses for demonstrating disease&#x2010;modifying effects in Alzheimer's disease. PLoS One. 2015;10(3):e0119632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4363486</ArticleId><ArticleId IdType="pubmed">25781335</ArticleId></ArticleIdList></Reference><Reference><Citation>Spineli LM, Jenz E, Gro&#xdf;hennig A, Koch A. Critical appraisal of arguments for the delayed&#x2010;start design proposed as alternative to the parallel&#x2010;group randomized clinical trial design in the field of rare disease. Orphanet J Rare Dis. 2017;12(1):140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5559817</ArticleId><ArticleId IdType="pubmed">28814322</ArticleId></ArticleIdList></Reference><Reference><Citation>Latimer NR, White IR, Abrams KR, Siebert U. Causal inference for long&#x2010;term survival in randomised trials with treatment switching: should re&#x2010;censoring be applied when estimating counterfactual survival times? Stat Methods Med Res. 2019;28(8):2475&#x2010;2493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6676341</ArticleId><ArticleId IdType="pubmed">29940824</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB, Karnon J. Adjusting for treatment switching in oncology trials: a systematic review and recommendations for reporting. Value Health. 2020;23(3):388&#x2010;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">32197735</ArticleId></ArticleIdList></Reference><Reference><Citation>Latimer NR, Abrams KR. NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. Vol 16. London: National Institute for Health and Care Excellence (NICE); 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">27466662</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>